Korea FDA Sends Precautionary Notice To Doctors For Diabetes Drugs Containing Rosiglitazone
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Food and Drug Administration issued its second precautionary notice to doctors, calling for caution in prescribing diabetes drugs containing rosiglitazone, including GlaxoSmithKline's Avandia and Avandaryl, Sanofi Aventis' Amavan, and local Korean Yuhan Corp.'s generic rosiglitazone
You may also be interested in...
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia
Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
In a new development following recent attention brought by a U.S. Senate Finance Committee report, the Saudi Arabia Food and Drug Authority has suspended the use of GlaxoSmithKline's Avandia (rosiglitazone) for six months while a review is under way